{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:11:06Z","timestamp":1790359866361,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.lungcan.2026.109405","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T16:21:43Z","timestamp":1775578903000},"page":"109405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Asia-Pacific practical consensus in the management of adverse events related to amivantamab-based therapies in non-small cell lung cancer"],"prefix":"10.1016","volume":"216","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3053-3997","authenticated-orcid":false,"given":"Ross A.","family":"Soo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4882-1564","authenticated-orcid":false,"given":"Pablo","family":"Fernandez-Penas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9638-9860","authenticated-orcid":false,"given":"Pei Jye","family":"Voon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6727-9435","authenticated-orcid":false,"given":"Junko","family":"Tanizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2341-4495","authenticated-orcid":false,"given":"Jeng-Sen","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0505-1814","authenticated-orcid":false,"given":"Chris","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao Rong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar","family":"Prabhash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Ryun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Parkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Kam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jairo","family":"Simoes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"McGeachie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Pavlakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109405_b0005","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2026.109405_b0010","article-title":"Consensus on the lung cancer management after third-generation EGFR-TKI resistance","volume":"53","author":"Zhou","year":"2024","journal-title":"Lancet. Reg. Health. West. Pac."},{"key":"10.1016\/j.lungcan.2026.109405_b0015","first-page":"2892","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"Midha","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109405_b0020","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1016\/j.jtho.2021.01.228","article-title":"MA04.07 Comparative clinical outcomes for patients with NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations","volume":"16","author":"Girard","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109405_b0025","article-title":"Targeting MET in NSCLC: an ever-expanding territory","volume":"5","author":"Han","year":"2024","journal-title":"JTO. Clin. Res. Rep."},{"key":"10.1016\/j.lungcan.2026.109405_b0030","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf194","article-title":"Mitigation and management of adverse events associated with amivantamab therapy","volume":"30","author":"Florez","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.lungcan.2026.109405_b0035","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cllc.2022.11.004","article-title":"Amivantamab, an epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) bispecific antibody, designed to enable multiple mechanisms of action and broad clinical applications","volume":"24","author":"Cho","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109405_b0040","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1158\/0008-5472.CAN-15-2833","article-title":"A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor\u2013resistant lung tumors","volume":"76","author":"Moores","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109405_b0045","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/1535-7163.MCT-20-0071","article-title":"Amivantamab (JNJ-61186372), an Fc enhanced EGFR\/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte\/macrophage trogocytosis","volume":"19","author":"Vijayaraghavan","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lungcan.2026.109405_b0050","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1158\/2159-8290.CD-20-0116","article-title":"Antitumor activity of amivantamab (JNJ-61186372), an EGFR\u2013MET bispecific antibody, in diverse models of EGFR exon 20 insertion\u2013driven NSCLC","volume":"10","author":"Yun","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2026.109405_b0055","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109405_b0060","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","article-title":"Overall survival with amivantamab-lazertinib in EGFR-mutated advanced NSCLC","volume":"393","author":"Yang","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109405_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108496","article-title":"Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset","volume":"204","author":"Cho","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109405_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2026.109305","article-title":"Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis","volume":"214","author":"Hayashi","year":"2026","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109405_b0075","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.jtho.2025.07.117","article-title":"Enhanced versus standard dermatologic management with amivantamab-lazertinib in EGFR-mutated advanced NSCLC: the COCOON global randomized controlled trial","volume":"20","author":"Cho","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109405_b0080","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/ajco.12687","article-title":"Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities","volume":"14","author":"Aw","year":"2018","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109405_b0085","doi-asserted-by":"crossref","first-page":"537","DOI":"10.5582\/bst.2018.01246","article-title":"Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors","volume":"12","author":"Peng","year":"2019","journal-title":"Biosci. Trends"},{"key":"10.1016\/j.lungcan.2026.109405_b0090","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/jjco\/hyv207","article-title":"Skin problems and EGFR-tyrosine kinase inhibitor","volume":"46","author":"Kozuki","year":"2016","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109405_b0095","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v104.40555","article-title":"Skin toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitors and their influence on treatment adjustments in lung cancer patients","volume":"104","author":"Lee","year":"2024","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.lungcan.2026.109405_b0100","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jfma.2024.07.029","volume":"124","author":"Lu","year":"2025","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1016\/j.lungcan.2026.109405_b0105","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3892\/mco.2017.1184","article-title":"Management of afatinib-induced stomatitis","volume":"6","author":"Kato","year":"2017","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109405_b0110","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s11523-022-00912-y","article-title":"Management of peripheral edema in patients with MET exon 14-mutated non-small cell lung cancer treated with small molecule MET inhibitors","volume":"17","author":"Nishio","year":"2022","journal-title":"Target. Oncol."},{"key":"10.1016\/j.lungcan.2026.109405_b0115","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231216089","article-title":"Chinese multidisciplinary expert consensus on the management of adverse drug reactions associated with savolitinib","volume":"15","author":"Zhang","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.lungcan.2026.109405_b0120","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.3390\/cancers16142526","article-title":"Management of skin toxicities in cancer treatment: an Australian\/New Zealand perspective","volume":"16","author":"Ladwa","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lungcan.2026.109405_b0125","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1080\/14796694.2025.2499511","article-title":"Navigating advanced lung cancer care, patient-physician alliance, cancer stigma, and psychosocial support in Asia-Pacific: perspectives from patients, caregivers, and physicians","volume":"21","author":"Lee","year":"2025","journal-title":"Future Oncol."},{"key":"10.1016\/j.lungcan.2026.109405_b0130","article-title":"Mechanism of lethal skin toxicities induced by epidermal growth factor receptor inhibitors and related treatment strategies","volume":"12","author":"Li","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2026.109405_b0135","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1186\/s40001-025-02925-5","article-title":"Dynamic association of serum albumin changes with inflammation, nutritional status and clinical outcomes: a secondary analysis of a large prospective observational cohort study","volume":"30","author":"Li","year":"2025","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.lungcan.2026.109405_b0140","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.cllc.2024.04.004","article-title":"Risk of venous thromboembolism in patients with stage III and IV non-small-cell lung cancer: nationwide descriptive cohort study","volume":"25","author":"Ording","year":"2024","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109405_b0145","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"ESMO Guidelines Committee, Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109405_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102922","article-title":"Management of infusion-related reactions in cancer therapy: strategies and challenges","volume":"9","author":"Barroso","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.lungcan.2026.109405_b0155","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109405_b0160","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.jtho.2025.06.030","article-title":"Lazertinib versus osimertinib in previously untreated EGFR-mutant advanced NSCLC: a randomized, double-blind, exploratory analysis from MARIPOSA","volume":"20","author":"Lee","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109405_b0165","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jtho.2025.01.018","article-title":"Preventing infusion-related reactions with intravenous amivantamab-results from SKIPPirr, a phase 2 study: a brief report","volume":"20","author":"Spira","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109405_b0170","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.24.01001","article-title":"Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory epidermal growth factor receptor\u2013mutated non\u2013small cell lung cancer: primary results from the phase III PALOMA-3 study","volume":"42","author":"Leighl","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109405_b0175","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/09546634.2017.1369494","article-title":"Review of the mechanism of action of coal tar in psoriasis","volume":"29","author":"Sekhon","year":"2018","journal-title":"J. Dermatolog. Treat."},{"key":"10.1016\/j.lungcan.2026.109405_b0180","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/bjd.14756","article-title":"Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysis","volume":"175","author":"Petrelli","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.lungcan.2026.109405_b0185","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/der2.49","article-title":"Treating acne with the tetracycline class of antibiotics: a review","volume":"2","author":"Graber","year":"2021","journal-title":"Dermatological Reviews"},{"key":"10.1016\/j.lungcan.2026.109405_b0190","unstructured":"Eliquis\u00ae (apixaban) tablets, for oral use [package insert]. Princeton, NJ: Bristol Myers Squibb Company; 2025."},{"key":"10.1016\/j.lungcan.2026.109405_b0195","unstructured":"XARELTO\u00ae (rivaroxaban) tablets, for oral use [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2026."},{"key":"10.1016\/j.lungcan.2026.109405_b0200","unstructured":"Lixiana film-coated tablets [product information]. Pfaffenhofen, Germany: Daiichi Sankyo Europe GmbH."},{"key":"10.1016\/j.lungcan.2026.109405_b0205","unstructured":"RYBREVANT\u00ae (amivantamab-vmjw) injection, for intravenous use [package insert]. Horsham, PA: Janssen Biotech, Inc.; Revised 2025."},{"key":"10.1016\/j.lungcan.2026.109405_b0210","unstructured":"H. Hayashi, B. Besse, S.H. Lee, S. Lu, D. Nguyen, S. Popat, J.C.H. Yang, M. Gottfried, J.M. Dias, C. Martin, M.A.N. \u015eendur, L. Paz-Ares, S. Owen, M.D.R.G. Campelo, B. Wang, S. Sethi, S. Shah, J. Zhang, J.C. Curtin, B.C. Cho, Mechanisms of acquired resistance to first-line amivantamab plus lazertinib vs osimertinib: updated analysis from MARIPOSA, Presented at: World Conference on Lung Cancer (WCLC); September 6\u20139, 2025; Barcelona, Spain."},{"key":"10.1016\/j.lungcan.2026.109405_b0215","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11523-025-01128-6","article-title":"The user's guide to amivantamab","volume":"20","author":"Brazel","year":"2025","journal-title":"Target. Oncol."},{"key":"10.1016\/j.lungcan.2026.109405_b0220","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3390\/cancers17020259","article-title":"Prevention and treatment of venous thromboembolism associated with amivantamab-based therapies in patients with lung cancer-provisional clinical opinion based on existing clinical practice guidelines","volume":"17","author":"Moik","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lungcan.2026.109405_b0225","doi-asserted-by":"crossref","first-page":"245","DOI":"10.6004\/jadpro.2024.15.4.2","article-title":"Infusion-related reaction management with amivantamab for EGFR exon 20 insertion mutation NSCLC: a practical guide for advanced practitioners","volume":"15","author":"Dougherty","year":"2024","journal-title":"J. Adv. Pract. Oncol."},{"key":"10.1016\/j.lungcan.2026.109405_b0230","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.lungcan.2023.02.008","article-title":"Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study","volume":"178","author":"Park","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109405_b0235","first-page":"1","article-title":"Cutaneous toxicities with amivantamab for non-small cell lung cancer: a practical guide and best practices","volume":"28","author":"Singh-Kandah","year":"2024","journal-title":"Clin. J. Oncol. Nurs."},{"key":"10.1016\/j.lungcan.2026.109405_b0240","doi-asserted-by":"crossref","first-page":"430","DOI":"10.4103\/apjon.apjon_33_18","article-title":"Team management of skin rash associated with use of epidermal growth factor receptor-tyrosine kinase inhibitors","volume":"5","author":"Masago","year":"2018","journal-title":"Asia Pac. J. Oncol. Nurs."},{"key":"10.1016\/j.lungcan.2026.109405_b0245","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/ijc.35512","article-title":"Optimizing management of stage IV EGFR mutant non-small cell lung cancer in Asia: an expert opinion","volume":"157","author":"Chang","year":"2025","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109405_b0250","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.21037\/tlcr-24-866","article-title":"Comprehensive management of MET tyrosine kinase inhibitor-induced peripheral edema in patients with MET-altered non-small-cell lung cancer: a narrative review","volume":"14","author":"Lin","year":"2025","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109405_b0255","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/jamadermatol.2025.3122","article-title":"Topical \u03b2-blocker wet wrap therapy for amivantamab-induced scalp and facial necrosis","volume":"161","author":"Chen","year":"2025","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.lungcan.2026.109405_b0260","doi-asserted-by":"crossref","unstructured":"J.C.H. Yang, Y.J. Kim, S.H. Lee, B. Liu, Y. Ostapenko, S. Lu, A. Alip, E. Korbenfeld, J.M. Mourao Dias, P. Danchaivijitr, N. Girard, E. Felip, H. Hayashi, A.I. Spira, B. Besse, T. Sun, M. Ennis, S. Sethi, J.M. Bauml, B.C. Cho, 4O Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: final overall survival (OS) from the phase, 3 MARIPOSA study, Presented at: European Lung Cancer Congress (ELCC); March 26\u201329, 2025; Paris, France.","DOI":"10.1016\/S1556-0864(25)00199-6"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T16:22:02Z","timestamp":1782663722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226004666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":52,"alternative-id":["S0169500226004666"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109405","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Asia-Pacific practical consensus in the management of adverse events related to amivantamab-based therapies in non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109405","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109405"}}